Conservative Otosclerosis Treatment With Sodium Fluoride and Other Modern Formulations: A Systematic Review.
bisphosphonates
hearing loss
otosclerosis
otospongiosis
sodium fluoride
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
accepted:
10
02
2023
entrez:
16
3
2023
pubmed:
17
3
2023
medline:
17
3
2023
Statut:
epublish
Résumé
Otosclerosis, also known as otospongiosis, is a primary osteodystrophy of the otic capsule of the inner ear and one of the leading causes of deafness in adults. The rationale for medical therapy for otospongiosis is to slow down and eventually stop the phase of bone resorption. Conservative treatments include sodium fluoride (NaF), bisphosphonates, and other modern medicines. A systematic review of the existing and published articles and books until April 2021 has been conducted in Medscape, Google Scholar, PubMed, and other databases using appropriate terms. According to the results of the research, the administration of NaF for a period of at least six months stabilizes hearing thresholds (HTs), improves vestibular symptoms, and delays the worsening of tinnitus. The administration of bisphosphonates for a period of at least six months showed significant percentage differences in the improvement of hearing loss, dizziness, and tinnitus remission. In the already existing double-blind studies that were evaluated, groups of patients treated with bisphosphonates for at least 24 months showed greater stabilization of the mean air and bone conduction thresholds than groups of patients treated with a placebo. The new modern medications have not yet been widely administered clinically to draw useful conclusions, although the test results of some of their use are quite encouraging.
Identifiants
pubmed: 36923175
doi: 10.7759/cureus.34850
pmc: PMC10008770
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e34850Informations de copyright
Copyright © 2023, Gogoulos et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Science. 1982 Sep 17;217(4565):1153-5
pubmed: 7112122
Eur Arch Otorhinolaryngol. 2009 Nov;266(11):1711-8
pubmed: 19340443
Otol Neurotol. 2008 Apr;29(3):295-301
pubmed: 18491423
Laryngoscope. 2005 Jan;115(1):172-7
pubmed: 15630389
Am J Otolaryngol. 2005 Mar-Apr;26(2):113-7
pubmed: 15742264
Otol Neurotol. 2006 Feb;27(2):276-81
pubmed: 16437001
J Biomed Mater Res. 2002 Jun 5;60(3):392-7
pubmed: 11920662
Br J Hosp Med (Lond). 2006 Sep;67(9):470, 472-6
pubmed: 17017609
Otolaryngol Head Neck Surg. 1985 Jun;93(3):313-21
pubmed: 3927224
Adv Otorhinolaryngol. 2007;65:17-24
pubmed: 17245018
JAAPA. 2017 Feb;30(2):17-22
pubmed: 28060022
Nat Rev Immunol. 2007 Apr;7(4):292-304
pubmed: 17380158
Am J Otol. 1992 Mar;13(2):124-6
pubmed: 1599002
Clin Otolaryngol Allied Sci. 2003 Apr;28(2):112-20
pubmed: 12680829
Braz J Otorhinolaryngol. 2012 Apr;78(2):73-9
pubmed: 22499373
Am J Otol. 1989 Jan;10(1):20-2
pubmed: 2655462
B-ENT. 2009;5(4):241-4
pubmed: 20163050
Ear Nose Throat J. 1997 Jun;76(6):371-6, 379-81
pubmed: 9210803
Audiol Neurootol. 2006;11(6):357-65
pubmed: 16988499
Laryngoscope Investig Otolaryngol. 2017 Sep 21;2(5):262-268
pubmed: 29094069
Eur Arch Otorhinolaryngol. 2009 Jan;266(1):25-35
pubmed: 18704474
Cureus. 2021 Mar 26;13(3):e14126
pubmed: 33927934
Int J Clin Pract. 2010 Jan;64(2):256-65
pubmed: 20089010
Otolaryngol Clin North Am. 2018 Apr;51(2):275-290
pubmed: 29502722
Acta Otolaryngol. 2001 Jan;121(2):174-7
pubmed: 11349772
Am J Otol. 1998 Sep;19(5):604-10
pubmed: 9752968
Eur Arch Otorhinolaryngol. 2007 Jul;264(7):741-8
pubmed: 17297608
PLoS One. 2010 Oct 11;5(10):e13305
pubmed: 20949013
PLoS One. 2011;6(9):e24285
pubmed: 21931671
Laryngorhinootologie. 1999 Jan;78(1):20-3
pubmed: 10080123
Eur Arch Otorhinolaryngol. 2010 Sep;267(9):1337-49
pubmed: 20532905
Am J Otol. 1993 Sep;14(5):482-90
pubmed: 8122713
Clin Drug Investig. 2007;27(6):419-33
pubmed: 17506592
Otolaryngol Clin North Am. 1993 Jun;26(3):491-502
pubmed: 8341576
Otol Neurotol. 2005 Nov;26(6):1128-33
pubmed: 16272929
Am J Otol. 1994 Jul;15(4):536-9
pubmed: 8588610
Autoimmun Rev. 2009 Dec;9(2):95-101
pubmed: 19318139
Int Tinnitus J. 2008;14(2):92-6
pubmed: 19205157
Ann Otol Rhinol Laryngol. 1974 Sep-Oct;83(5):635-42
pubmed: 4416065
Clin Otolaryngol. 2022 Nov;47(6):708-716
pubmed: 34971491
J Int Adv Otol. 2019 Aug;15(2):277-282
pubmed: 31418718
Am J Otol. 1986 Mar;7(2):121-5
pubmed: 3963156
Am J Otol. 2000 Nov;21(6):809-12
pubmed: 11078068
Acta Chir Hung. 1992-1993;33(1-2):101-7
pubmed: 1343452
Curr Opin Rheumatol. 2009 Jul;21(4):369-73
pubmed: 19424068
Otolaryngol Head Neck Surg. 1993 Sep;109(3 Pt 1):461-7
pubmed: 8414563
Ann N Y Acad Sci. 2007 Aug;1109:385-400
pubmed: 17785327
Science. 2000 Sep 1;289(5484):1504-8
pubmed: 10968780
Laryngoscope. 2007 Mar;117(3):552-5
pubmed: 17334321
Eur Arch Otorhinolaryngol. 2013 Mar;270(3):793-804
pubmed: 22843095
Endocr Pract. 2011 Mar-Apr;17 Suppl 1:26-30
pubmed: 21134875
Hum Genet. 2008 Apr;123(3):267-72
pubmed: 18224337
Otolaryngol Pol. 2011 May-Jun;65(3):162-70
pubmed: 21916215
Xenobiotica. 2009 Feb;39(2):113-24
pubmed: 19255937
Ann Otol Rhinol Laryngol. 1978 Nov-Dec;87(6 Pt 1):778-96
pubmed: 310648
Laryngoscope. 2005 Jul;115(7):1291-7
pubmed: 15995524
Rev Laryngol Otol Rhinol (Bord). 1977 May-Jun;98(5-6):221-5
pubmed: 897403
Mayo Clin Proc. 2009 Jul;84(7):632-7; quiz 638
pubmed: 19567717
Laryngoscope. 2010 Jun;120(6):1195-202
pubmed: 20513039
Audiol Neurootol. 2003 Nov-Dec;8(6):316-21
pubmed: 14566102
Otol Neurotol. 2012 Oct;33(8):1308-14
pubmed: 22935809
Ann Otol Rhinol Laryngol. 2009 Dec;118(12):859-65
pubmed: 20112520
Acta Otolaryngol Suppl. 1990;470:130-9; discussion 139-40
pubmed: 2173335
Int J Clin Pract. 2009 Oct;63(10):1526-30
pubmed: 19769709
Eur Arch Otorhinolaryngol. 2011 Mar;268(3):357-65
pubmed: 20963600
Laryngoscope. 2006 Aug;116(8):1427-33
pubmed: 16885748
Otolaryngol Clin North Am. 2018 Apr;51(2):441-452
pubmed: 29502728
Exp Physiol. 2001 May;86(3):373-9
pubmed: 11429655